BIO International Convention 2012 Preview - Part III

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

BIO and the America Invents Act

[author: Andrew Williams]

BIO International ConventionThe 2012 BIO International Convention begins in Boston next week.  Patent Docs has been highlighting a few sessions, in thematic fashion, to help you navigate your way through the convention.  Today, in this final installment, we review a few opportunities for those interested in learning how the Leahy-Smith America Invents Act will impact U.S. patent practice, with the use of patent systems from other countries to serve as a guide.  Please note, however, that even though we have highlighted several sessions from a spectrum of disciplinary tracks over the past week, we have only begun to scratch the surface of opportunities available at the BIO convention.  Of course, if you want to share your favorite session with us, or let us know how the America Invents Act is going to affect you or your company (or for that matter, any other topic that is on your mind), the Patent Docs authors and contributors will be present at BIO as part of the MBHB contingent, and you are encouraged to stop by the MBHB booth to meet us (#1335 – Hall A).  We will be posting a schedule shortly to let you know when your favorite Patent Docs author or contributor will be at the booth.

As Patent Docs readers know, one of the biggest stories from the past year for U.S. patent practice was the passage of the Leahy-Smith America Invents Act ("the AIA").  Of course, Patent Docs has been covering the AIA for years, and is continuing to follow the U.S. Patent Office's implementation of various provisions of the new law.  There has been no shortage of opportunities to learn about and discuss the AIA, but the BIO International Convention provides some unique opportunities that are not necessarily found elsewhere.  Specifically, the U.S. can look to how patent systems throughout the world have been dealing with provisions that are analogous to sections of the AIA.  Because of the strong international presence at the conference, U.S. patent practitioners can learn from their international colleagues.  And, hopefully, it will also give the non-U.S. patent practitioners a chance to learn about how the new U.S. law will affect them and their companies or clients.

As a perfect example, the Biotech Patenting and Tech Transfer Track will be presenting "Patenting under the America Invents Act in Comparison with European Patent Practice" on Wednesday, June 20, between 10:00-11:30 am.  This session will include speakers from the European Patent Office and the U.S. Patent and Trademark Office, as well as patent practitioners from these two jurisdictions, who will be able to provide insight on the America Invents Act and how it compares to European practice.  The session promises to review the changes in patentability in the U.S., such as the first-to-file system, the grace period, prior art, and post grant review, and assess patentability in Europe, including its first-to-file system, prior art, and opposition practice.  These two systems will be compared and contrasted for perspectives on global strategies.  For example, the differences in the grace periods related to the two first-to-file systems will be examined, including how they might impact prosecution strategies.  The speakers of this session include Wenfang Chen, Patent Counsel for Danisco U.S. Inc./Dupont; Sally Mannion, Head, Pharma & Nutrition Team at Avidity IP; Enrique Molina Galán, Director, European Patent Office; and Mary Till, Legal Advisor with the U.S. Patent and Trademark Office.  This session will be moderated by Thomas Kowalski, Shareholder at Vedder Price.

Another example of a session that will look to other jurisdictions, this time for a specific topic, is "The New World: Post-Grant Review in the United States -- What Can We Learn from Experiences in Europe, Japan, India and Australia," which is being presented on Monday, June 18, between 2:00-3:30 pm.  The AIA made significant changes to the U.S. post-grant review system, allowing parties the opportunity to challenge the validity of patents on prior art and disclosure grounds within nine months of grant.  There will be a newly titled "Patent Trial and Appeal Board" that will hear these challenges, and the Federal Circuit will only be able to review decisions under the substantial evidence standard.  The speakers for this session are a panel of international experts who will be able to explain their countries' histories with post-grant review, including the growing pains they experienced developing their respective systems.  They promise to assess the pros and cons of post-grant review and coordinated global approaches to the subject.  The session includes Pravin Anand, Managing Partner at Anand and Anand; Katrina Howard, Member, Selborne Chambers; Hans-Rainer Jaenichen, Partner at Vossius & Partner; and Shusaku Yamamoto, Founder of Shusaku Yamamoto Patent Attorneys.  The session will be moderated by James F. Haley, Partner at Ropes & Gray LLP.

The final session that we are highlighting will explore the consequences, whether intentional or unintentional, of one of the provisions of the AIA -- the Prior User Rights.  This session is entitled "Prior User Rights and Trade Secrets: A New IP Option Replacing Patents to Secure Freedom-To-Operate for Internally Used Innovations in Biotechnology," and will be presented on Tuesday, June 19, and 2:00-3:30 pm.  This section of the AIA allows a company to maintain a new technology as a trade secret, while providing a defense against future infringement of a later patent.  As such, the Prior User Rights could change the patent landscape for externally marketed products and internally used technologies used to produce them.  This session promises to assess the merits and risks of the choice between patents and prior user rights to secure freedom-to-operate for these internally used technologies.  It will also explore how a prior user paradigm might best benefit you or your clients company.  The speakers for this session include Brian Barrett, Associate General Patent Counsel for Eli Lilly & Company; Mary Ann Dillahunty, Vice President, Intellectual Property for Oncolytics Biotech, Inc.; Jason Duncan, Associate General Counsel of EMD Serono, Inc.; and Andrew Torrance, Visiting Professor at MIT Sloan School of Management.  The moderators will be Thomas Kelley, Consulting Patent Counsel of Monsanto Company and R. Mark Halligan, Partner at Nixon Peabody LLP.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.